Cover Image

Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece

Aim: This study assessed the clinical impact and cost-effectiveness of switching from tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) in a Greek chronic hepatitis B (CHB) population. Patients & methods: A Markov model from the perspective of a third-p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Emmanouil Sinakos (Author), Nandita Kachru (Author), Christos Tsoulas (Author), Sushanth Jeyakumar (Author), Nathaniel J Smith (Author), Alon Yehoshua (Author), Evangelos Cholongitas (Author)
Format:	Book
Published:	Becaris Publishing Limited, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
by: Jared M. Gilbert, et al.
Published: (2022)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
by: Suzuki F, et al.
Published: (2014)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
by: Man Li, et al.
Published: (2023)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019)

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
by: Li X, et al.
Published: (2021)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
by: Kensuke Abe, et al.
Published: (2024)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
by: Hannes Lengauer, et al.
Published: (2020)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
by: Linden Lalley-Chareczko, et al.
Published: (2020)

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review
by: Iulia Baciu, et al.
Published: (2021)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
by: Laura Waters, et al.
Published: (2021)

Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density-A Scoping Review of the Literature
by: Tejpal Singh Hashwin Singh, et al.
Published: (2024)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
by: Laura Else, et al.
Published: (2022)

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya
by: Jillian Pintye, et al.
Published: (2015)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
by: Yang YM, et al.
Published: (2017)

A review of Tenofovir Disoproxil Fumarate associated nephrotoxicity among People Living with HIV: Burden, risk factors and solutions
by: Edwin Sam Asirvatham, et al.
Published: (2024)

GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice gut-microbiota-dependent anti-inflammation
by: Hao Liu, et al.
Published: (2019)

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review
by: Maria Brennda Ferreira de Gusmão, et al.
Published: (2023)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
by: Nagalingeswaran Kumarasamy, et al.
Published: (2018)

Comparative application of derivative spectrophotometric and HPLC techniques for the simultaneous determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combined drugs
by: Edebi N. Vaikosen, et al.
Published: (2023)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
by: Ashana Puri, et al.
Published: (2019)

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC
by: Shweta Sharma, et al.
Published: (2020)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017)

Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients
by: Hiroki Yagura, et al.
Published: (2024)

A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects
by: Kim YK, et al.
Published: (2017)

A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation
by: Swetha Addanki, et al.
Published: (2021)

Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B
by: Beatriz López Centeno, et al.
Published: (2016)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
by: Manjula Gunawardana, et al.
Published: (2020)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
by: Lanqing Li, et al.
Published: (2023)

Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant
by: Fernanda P. Pons-Faudoa, et al.
Published: (2020)

Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
by: McNeil Ngongondo, et al.
Published: (2024)